Clinical Trial Detail

NCT ID NCT02628067
Title Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

bile duct carcinoma

lung small cell carcinoma

thyroid gland carcinoma

Advanced Solid Tumor

malignant mesothelioma

cholangiocarcinoma

salivary gland cancer

endometrial carcinoma

gallbladder adenocarcinoma

neuroendocrine tumor

cervix carcinoma

vulva carcinoma

anal canal carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.